Daiichi Sankyo will present over 45 abstracts showcasing new clinical research in various cancers at the 2024 ESMO Asia Congress, San Antonio Breast Cancer Symposium (SABCS), and American Society of Hematology (ASH) Annual Meeting, leading up to its Science & Technology Day. These presentations will highlight the company’s progress in establishing new standards of cancer care.
Key late-breaking presentations include a pooled analysis from the TROPION-Lung05 and TROPION-Lung01 trials of datopotamab deruxtecan (Dato-DXd) in EGFR-mutated advanced non-small cell lung cancer (NSCLC) at ESMO Asia. SABCS will feature a subgroup analysis from the DESTINY-Breast06 trial of ENHERTU (trastuzumab deruxtecan) in HR positive, HER2 low or ultralow breast cancer and the primary analysis from the VALENTINE trial of patritumab deruxtecan (HER3-DXd) in early HR positive, HER2 negative breast cancer. These presentations cover advancements in challenging cancers like lung, breast, gastric, biliary tract, acute myeloid leukemia, and peripheral T-cell lymphoma.
ESMO Asia will showcase lung cancer innovation with the Dato-DXd analysis in EGFR-mutated NSCLC. Mini oral presentations will feature the TROPION-Breast01 trial of Dato-DXd in Chinese patients with metastatic HR positive, HER2 low or negative breast cancer, and final results from the DESTINY-Gastric06 trial of ENHERTU in Chinese patients with HER2 positive advanced gastric or gastroesophageal junction adenocarcinoma. This latter trial led to ENHERTU’s conditional approval in China for this indication. Trials-in-progress posters will detail ongoing ENHERTU trials, including DESTINY-BTC01 evaluating ENHERTU with rilvegostomig in biliary tract cancer and DESTINY-Gastric03 evaluating ENHERTU combined with rilvegostomig and chemotherapy in gastric or GEJ adenocarcinoma. The DESTINY-PanTumor02 trial of ENHERTU will expand to include new cohorts of various HER2-expressing solid tumors.
SABCS will present breast cancer advancements, including a DESTINY-Breast06 subgroup analysis examining the impact of prior endocrine therapy response on ENHERTU outcomes in HR positive, HER2 low or ultralow breast cancer. Primary results from the VALENTINE trial evaluating neoadjuvant HER3-DXd, alone or with letrozole, in high-risk HR positive, HER2 negative early breast cancer will also be presented. Additional data includes biomarker analysis from DESTINY-Breast03 assessing the impact of genomic alterations on ENHERTU compared to T-DM1 in HER2 positive metastatic breast cancer, and quality of life and neurological function data from DESTINY-Breast12. Final results from the DESTINY-Breast08 dose expansion, evaluating ENHERTU with capecitabine or capivasertib in HER2 low metastatic breast cancer, will also be presented.
At ASH, several sub-analyses of the QuANTUM-First trial of VANFLYTA (quizartinib) in newly diagnosed FLT3-ITD positive AML will be presented, including data on co-mutations and their impact on outcomes, and the effect of continuation therapy. Further presentations will focus on the QUIWI trial evaluating VANFLYTA with chemotherapy in FLT3-ITD negative AML, including final results and sub-analyses. The QuANTUM-Wild phase 3 trial design, based on QUIWI, will also be presented. Additionally, results from the VALYM trial of valemetostat in relapsed/refractory large B-cell lymphoma and an analysis of circulating tumor DNA from the VALENTINE-PTCL01 trial in relapsed/refractory peripheral T-cell lymphoma will be shared.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
